SANOFI-ADR (SNY)

US80105N1054 - ADR

47.98  +0.2 (+0.42%)

After market: 47.98 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

SANOFI-ADR

NASDAQ:SNY (11/21/2024, 8:00:02 PM)

After market: 47.98 0 (0%)

47.98

+0.2 (+0.42%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-1.15%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap120.28B
Shares
PE11.32
Fwd PE10.43
Dividend Yield3.98%
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

SNY Daily chart

Company Profile

Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 87,994 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.

Company Info

SANOFI-ADR

46 Avenue de la Grande Armee

Paris ILE-DE-FRANCE 75008

P: 33153774000

CEO: Paul Hudson

Employees: 86088

Website: https://www.sanofi.com/

SNY News

News Image7 days ago - Regeneron Pharmaceuticals, Inc.Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
ChartMill News Image15 days ago - ChartmillNASDAQ:SNY stands out as a stock that provides good value for the fundamentals it showcases.

SANOFI-ADR (NASDAQ:SNY) is probably undervalued for the fundamentals it is displaying.

News Image16 days ago - Regeneron Pharmaceuticals, Inc.Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
News Image25 days ago - The Motley FoolStock-Split Watch: 2 Healthcare Stocks That Look Ready to Split

One of these players has split its stock in the past. The other one hasn't.

News Imagea month ago - The Motley FoolWhy Sanofi Stock Flew Higher on Friday

No investor can ignore a crushing bottom-line beat and raised profitability guidance.

News Imagea month ago - The Motley FoolSanofi (SNY) Q3 2024 Earnings Call Transcript

SNY earnings call for the period ending September 30, 2024.

SNY Twits

Here you can normally see the latest stock twits on SNY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example